NEW YORK, Jan. 26, 2022 /PRNewswire/ -- The Gross Law Firm, securities class action litigators, issues the following notice to shareholders of Revance Therapeutics, Inc.:
Shareholders who purchased shares of RVNC during the class period listed below are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form/?id=22513&from=4
Class Period: November 25, 2019 to October 11, 2021
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) quality control deficiencies existed at the Company's manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE FEBRUARY 8, 2022: Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form/?id=22513&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RVNC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm's mission is to protect the rights of all investors who have suffered as the result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. Our team puts in the work to get the maximum recovery on behalf of investors. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-revance-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-8-2022--rvnc-301469019.html
SOURCE The Gross Law Firm
